-
Bristol-Myers Squibb Launches Zeposia in China for Multiple Sclerosis Treatment
•
Global pharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced the market launch in China of Zeposia (ozanimod), the world’s first selective sphingosine-1-phosphate (S1P) receptor modulator indicated for the treatment of recurrent multiple sclerosis (MS). This includes clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis. Mode…
-
Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial
•
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from the US FDA for its investigational drug ZG006, intended to treat small-cell lung cancer and other solid tumors. ZG006: A Tri-Specific Antibody Targeting CD3 and DLL3 EpitopesZG006 is a tri-specific antibody developed through the company’s…
-
JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial
•
China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National Medical Products Administration (NMPA) for its product Carteyva (relmacabtagene autoleucel injection; relma-cel). The treatment will be assessed for its efficacy in managing moderate-to-severe refractory systemic lupus erythematosus (SLE). Understanding Systemic Lupus Erythematosus (SLE)SLE is a…
-
Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China
•
China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine’s dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million…
-
CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine drug Ayvakit (avapritinib) in an effort to alleviate the financial burden on patients and enhance drug accessibility. The new prices for the 100mg and 300mg versions of the drug are now set at RMB 17,207…
-
Hangzhou Baikai Biomedical and Leads Biolabs Partner to Develop Innovative ADCs
•
China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed at developing multiple novel antibody-drug conjugates (ADCs). The collaboration combines the expertise of both companies to advance the development of innovative cancer treatments. Financial details of the partnership have not been disclosed. Baikai Bi’s ADC…
-
Cuban-Chinese Biotechnology Center Showcases Drug and Vaccine Progress to Cuban Delegation
•
Researchers from Cuba and China at the Yongzhou joint biotechnology innovation center in China’s Hunan Province recently presented updates on their drug and vaccine development projects to a diplomatic delegation from Cuba. Established in 2021, the bi-national institution has a robust pipeline that encompasses cancer, neurology, and infectious diseases, including…
-
Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments
•
The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig (ponatinib) is on track to obtain priority review status for the treatment of specific leukemia conditions in China. These include chronic myeloid leukemia (CML) that is resistant or intolerant to previous medications, recurrent or refractory…
-
Arctic Vision Partners with Sinopharm Group for Ophthalmic Product Distribution in China
•
China-based ophthalmology specialist Arctic Vision has entered into a strategic partnership with Sinopharm Group Distribution Co., Ltd. The collaboration aims to enhance the importation and national commercial distribution of Arctic Vision’s range of ophthalmic products across China. Expanding Distribution and Logistics ServicesUnder the terms of the agreement, Sinopharm Group Distribution…
-
Bioyond Robotics Secures $29 Million in Series A and A+ Financing Rounds
•
Bioyond Robotics, a Shanghai-based intelligent automation company, has reportedly raised around RMB 200 million (USD 29 million) through Series A and A+ financing rounds. The Series A+ funding was co-led by BioTrack Capital and Lilly Asia Fund (LAV), with CICC Qide Fund, a subsidiary of CICC Capital, joining the round.…
-
Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D
•
China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has reportedly raised tens of millions of renminbi in a Series A financing round. The funding round was led by Jiarui Investment and Hesheng Venture Capital. The proceeds from this investment will be directed towards the…
-
Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai
•
Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a new, state-of-the-art cell and gene therapy (CGT) GMP facility in Shanghai on March 31. This marks the company’s second facility, following the opening of a US-based facility in January. Investment and Global Impact of the…
-
Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase III clinical study for its Category 1 chemical drug XY0206, which targets recurrent/refractory acute myeloid leukemia (AML) patients with FLT3-ITD mutation (FMS-like tyrosine kinase 3 internal tandem duplication). XY0206: A Promising Multi-Target Tyrosine Kinase InhibitorXY0206…
-
Jiangsu Yuyue Medical Secures NMPA Approval for Semi-Automatic External Defibrillator
•
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223), a China-based medical device company, has announced that it has received medical device marketing approval from the National Medical Products Administration (NMPA) for its semi-automatic external defibrillator (AED). Innovative Features of the AED ProductThe newly approved AED comes equipped with…
-
MicuRx Pharmaceuticals Initiates Phase III Study for MRX-4 in Diabetic Foot Infection Treatment
•
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study for its novel anti-microbial agent MRX-4, used in combination with contezolid (MRX-I), as a sequential treatment for diabetic foot infection in China. Global Multi-Center Phase III Study Design and ApprovalThe global multi-center, randomized, double-blind Phase…
-
AstraZeneca Partners with Guangzhou Institute to Advance Respiratory Medicine Research
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute of Respiratory Health National Center for Respiratory Medicine. The collaboration will focus on enhancing efforts in basic medicine, translational medicine, and clinical medical research. The partnership aims to explore the collection and clinical application of…
-
Indonesia and China Deepen Healthcare Ties with High-Level Dialogue and New Agreements
•
Indonesia’s deputy minister of health, Dante Saksono Harbuwono, visited China last week as part of the third health-focused ‘High-Level Dialogue’ between the two nations. The visit encompassed a bilateral meeting with Harbuwono’s counterpart in the National Health Commission (NHC) of China and the witnessing of a significant cooperation agreement signing…
-
TYK Medicines Secures FDA Approval for Next-Generation TKI Clinical Trial
•
China-based TYK Medicines, Inc. has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its in-house developed next-generation tyrosine kinase inhibitor (TKI). This marks a significant step forward in the development of the company’s pipeline, with a separate clinical trial filing for…
-
Sequanta Technologies Partners with Element Biosciences to Expand Single-Cell Applications
•
Shanghai-based Sequanta Technologies, a leading multi-omics research and clinical service provider, has announced a strategic partnership with US firm Element Biosciences. With the integration of Element’s sequencing platform, the AVITI system, Sequanta is poised to enhance its focus on single-cell applications. The terms of the financial agreement have not been…
